

DCAT TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



****DCAT Sharp Sourcing Early Bird Rate Ends Today!****

1. Sandoz Progresses \$1 Billion Biomanufacturing Plan for Biosimilars

Sandoz, a Novartis division, plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020 and invest \$1 billion as part of a 2010-2020 investment scheme in biomanufacturing facilities in Schafnau and Kundl, Austria. The five launches will be enabled by a regulatory submissions strategy of 11 filings over a three-year period (2015-2017). [Read More](#)

2. Mylan Proceeds with Acquisition of Meda

Mylan N.V. has confirmed that the Attorney General of the Netherlands has rejected the request of the Dutch group VEB to initiate enquiry proceedings at the Enterprise Chamber of the Amsterdam Court of Appeal with respect of VEB's opinion that Mylan's shareholders should approve its recently announced public offer for all shares in Meda AB, a Swedish specialty pharmaceutical company. [Read More](#)

3. Pfizer Completes \$5.2 Billion Acquisition of Anacor Pharmaceuticals

Pfizer has completed its previously announced \$5.2 billion acquisition of Anacor Pharmaceuticals, a biopharmaceutical company developing and commercializing small-molecule drugs from its boron chemistry platform. [Read More](#)

4. Impax To Acquire Generic Portfolio from Teva for \$586 Million

Impax Laboratories, a specialty pharmaceutical company, has signed definitive agreements with Teva Pharmaceutical Industries and affiliates of Allergan for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application for the generic equivalent to Concerta (methylphenidate hydrochloride) for an aggregate purchase price of \$586 million. [Read More](#)

5. Perrigo Sells US Vitamins, Minerals & Supplements Business

Perrigo Company has agreed to sell its US Vitamins, Minerals & Supplements (VMS) business to International Vitamin Corporation (IVC). The transaction is subject to customary closing conditions and is expected to close by early August. [Read More](#)

6. Mitsubishi Gas Chemical, Nippon Kayaku Form mAb JV

Mitsubishi Gas Chemical and Nippon Kayaku have established a new joint venture company, Cultivecs, for the production of monoclonal antibody pharmaceuticals, including biosimilars. The company aims to start operation of a manufacturing facility in Japan within two years. [Read More](#)

7. AstraZeneca, Teva Settle Byetta Patent Litigation

Teva Pharmaceuticals USA has settled patent litigation with AstraZeneca and has entered into a

settlement and license agreement with AstraZeneca which allows Teva to commercialize its generic version of the Type II diabetes drug, Byetta (exenatide injection), in the US beginning October 15, 2017. Byetta posted 2015 sales of \$316 million. [Read More](#)

8. AstraZeneca Plans \$80 Million Charge Due To CDC Finding on Nasal Flu Vaccine

An advisory committee of the Centers for Disease Control and Prevention (CDC) has recommended that AstraZeneca's nasal flu vaccine, FluMist Quadrivalent, not be used in any setting, based on CDC vaccine effectiveness data from the last three influenza seasons in the US, which indicated it did not demonstrate statistically significant effectiveness. AstraZeneca plans to take a charge of \$80 million due to anticipated low demand for the vaccine. [Read More](#)

9. President Obama Signs Law for TSCA Reform

President Barack Obama signed into law legislation that reformed the Toxic Control Substances Control Act (TSCA). TSCA, first passed by Congress in 1976 and administered by the Environmental Protection Agency regulates the introduction of new or already existing chemicals in the US. [Read More](#)

10. Amgen Names New EVP of Operations and SVP of Manufacturing

Amgen has appointed Esteban Santos as executive vice president of operations, effective July 25, 2016, reporting to Robert A. Bradway, chairman and chief executive officer. Santos will be responsible for Amgen's Operations organization, which encompasses manufacturing, process development, quality, engineering and global supply chain. He will succeed Madhavan Balachandran, who is retiring at the end of the year. [Read More](#)

****Upcoming DCAT Event****

DCAT Announces Its Newest Member Networking Event

Enjoy all that Barcelona has to offer while making valuable industry connections at **DCAT After the Show**, DCAT's newest member networking event held immediately following CPhI Worldwide in Barcelona on Wednesday, October 5, from 6:00 PM to 8:30 PM. Located at the beautiful Casa Llotja de Mar, this venue is just steps away from the Gothic Quarter and Port of Barcelona, offering member company representatives the perfect opportunity to engage with colleagues they may have missed at the show before attending their customer events.

Registration for this event will open July 20, 2016. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org